Home › Funds › Soleus Capital Management, L.P. › RIGL
Soleus Capital Management, L.P. position in RIGL
RIGEL PHARMACEUTICALS INC · Health Care
Soleus Capital Management, L.P. reported holding 1,843,504 shares of RIGL (RIGEL PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$88.8M, representing 3.16% of its reported portfolio and ranking #7 among its reported holdings. Soleus Capital Management, L.P. has disclosed RIGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s RIGL position evolved
Soleus Capital Management, L.P. first disclosed a stake in RIGL in Q3 2023 at 14,803,015 shares (US$16.0M). The position peaked in Q3 2026 at 1,843,504 shares, worth US$88.8M. Across 13 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 8 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,843,504 shares valued at US$88.8M. Notable position changes include a 89% trim in Q2 2024 (shares rose 97% over the following quarter), a 97% trim in Q1 2026 (shares rose 45% over the following quarter), a 18335% increase in Q2 2026 (shares rose 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 14.80M | $15.99M | New |
| Q4 2023 | 9.44M | $13.69M | Reduce |
| Q1 2024 | 9.24M | $13.68M | Reduce |
| Q2 2024 | 1.04M | $8.58M | Reduce |
| Q3 2024 | 934.79K | $15.12M | Reduce |
| Q4 2024 | 1.13M | $19.02M | Add |
| Q1 2025 | 1.13M | $20.34M | Hold |
| Q2 2025 | 658.14K | $12.33M | Reduce |
| Q3 2025 | 330.01K | $9.35M | Reduce |
| Q4 2025 | 300.03K | $12.85M | Reduce |
| Q1 2026 | 10.00K | $270.40K | Reduce |
| Q2 2026 | 1.84M | $72.12M | Add |
| Q3 2026 | 1.84M | $88.76M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RIGL and 13F data
RIGL (RIGEL PHARMACEUTICALS INC) is a Health Care company. 43 other funds we track also report a position in RIGL — the largest reported positions include ARMISTICE CAPITAL, LLC (US$74.0M), CM Management, LLC (US$12.0M), GLOBEFLEX CAPITAL L P (US$5.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RIGL
- ARMISTICE CAPITAL, LLC 1.54M sh · $73.96M · Q3 2026
- CM Management, LLC 250.00K sh · $12.04M · Q3 2026
- GLOBEFLEX CAPITAL L P 112.67K sh · $5.43M · Q3 2026
- Lionhunter Capital Management, LLC 70.05K sh · $3.37M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held RIGL?
Soleus Capital Management, L.P. has disclosed RIGL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in RIGL?
As of Q3 2026, Soleus Capital Management, L.P. holds 1.84M shares of RIGL (RIGEL PHARMACEUTICALS INC), valued at $88.76M, representing 3.16% of its reported portfolio and ranking #7.
Has Soleus Capital Management, L.P. been buying or selling RIGL?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. held unchanged its position in RIGL. The position peaked in Q3 2026 at 1.84M shares.
Which other funds hold RIGL?
Other major institutional holders of RIGL include ARMISTICE CAPITAL, LLC, CM Management, LLC, GLOBEFLEX CAPITAL L P, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.